SCHEMBL18159978

SCHEMBL18159978

Cc1[nH]nc(N/C(=N\C(=O)c2ccc(F)c(F)c2)Nc2cc(F)cc(Cl)c2)c1C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.39
KCNQ3 O43525 4/20 0.35
KCNQ2 O43526 4/20 0.35
KCNQ5 Q9NR82 2/20 0.35
CHUK O15111 1/20 0.35
RAPGEF3 O95398 1/20 0.34
RAPGEF4 Q8WZA2 1/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
KCNE1 P15382 2/20 0.34
KCNQ1 P51787 2/20 0.34
GRM4 Q14833 2/20 0.34
POLB P06746 1/20 0.34
HTR5A P47898 3/20 0.33
CSNK2A1 P68400 1/20 0.32
RAF1 P04049 1/20 0.32
CES2 O00748 1/20 0.32
CES1 P23141 1/20 0.32
SLC10A1 Q14973 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18159987 0.90 CYP2D6 (0.50) CYP2D6CHUKMEN1KMT2AGRM4
SCHEMBL16797226 0.89 CYP2D6 (0.42) CYP2D6KCNQ3KCNQ2KCNQ5CHUK
SCHEMBL16797227 0.89 CYP2D6 (0.42) CYP2D6KCNQ3KCNQ2KCNQ5CHUK
SCHEMBL9920888 0.85 NPC1 (0.43) CYP2D6KCNQ3KCNQ2KCNQ5RAPGEF3
SCHEMBL19592072 0.81 CYP2D6 (0.42) CYP2D6KCNQ3KCNQ2KCNQ5RAPGEF3
SCHEMBL18162883 0.79 CYP2D6 (0.53) CYP2D6CHUKRAPGEF3RAPGEF4MEN1
SCHEMBL18557848 0.79 RAB9A (0.42) CYP2D6KCNQ3KCNQ2KCNQ5MEN1
SCHEMBL18557714 0.79 CYP2D6 (0.39) CYP2D6KCNQ3KCNQ2KCNQ5MEN1
SCHEMBL19041677 0.78 CYP2D6 (0.39) CYP2D6KCNQ3KCNQ2KCNQ5RAPGEF3
SCHEMBL18162905 0.78 CYP2D6 (0.52) CYP2D6KCNQ3KCNQ2KCNQ5RAPGEF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9815791-B2 Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-11-14 US disclosed
US-9815791-B2 Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-11-14 US disclosed
US-20160304465-A1 ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2016-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304465-A1 ALKYLPYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME CYP2D6 1739/4885KCNQ3 1665/4885KCNQ2 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.